Open label trial of naltrexone implants: Measuring blood serum levels of naltrexone

11Citations
Citations of this article
27Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The usefulness of oral naltrexone has been limited by compliance. Sub-cutaneous implants would seem to offer a solution to this problem and improve long-term outcomes. The aim of the present study was to compare levels of blood serum naltrexone of patients who had received a naltrexone implant after detoxification to a number of dependent variables of interest. These dependent variables included drug use including urine screens of each patient, any adverse response to the implant, subjective evaluation of self-esteem, quality of relationships, and changes in social functioning. Sixty six patients received an implant and were surveyed; urine and blood samples were taken at about 1, 3, and 6 months after implantation. Naltrexone levels were on average above 1 ng/mL at 6 months after insertion and patients showed significant improvements on all dependent variables. The preliminary evidence indicates that implants can improve compliance rates and outcomes. © the author(s), publisher and licensee Libertas Academica Ltd.

Cite

CITATION STYLE

APA

Colquhoun, R. M. (2013). Open label trial of naltrexone implants: Measuring blood serum levels of naltrexone. Substance Abuse: Research and Treatment, 7, 75–84. https://doi.org/10.4137/SART.S10776

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free